Tuesday, September 30, 2014

Allakos Gets $10M More

San Mateo-based Allakos, a biotechnology company developing antibody-based therapeutics for allergic diseases, inflammation, and other related conditions, said today that it has raised $10M more in a Series A funding. The new funds bring its total Series A to $42M. The funding came from Novo Ventures, Alta Partners, RiverVest Venture Partners and the Roche Venture Fund--all existing investors. Allakos is led by Dr. Christopher Bebbington. More information »